Evidence map›Paper›PMID 42217757›Full record

Trial reportJournal of pain and symptom management2026

Pilot Randomized Trial of a Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer.

Kelsey S Lau-Min, Riley Psenka, Mia Holtze, Cynthia Metri, Andrea Hansen, Stephen B Lo, Veronica Decker, Christopher R Manz, Aparna Parikh, Ryan Nipp and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of pain and symptom management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kelsey S Lau-MinDivision of Hematology/Oncology (K.S.L.M., A.H., A.P., A.E.J., J.S.T.), Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Cancer Outcomes Research and Education Program (K.S.L.M., C.M., S.B.L., R.N., A.E.J., J.S.T., L.T.), Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. Electronic address: klau-min@mgh.harvard.edu.
Riley PsenkaMedical University of South Carolina College of Medicine (R.P.), Charleston, South Carolina, USA.
Mia HoltzeFerkauf Graduate School of Psychology (M.H.), Yeshiva University, Bronx, New York, USA.
Cynthia MetriCancer Outcomes Research and Education Program (K.S.L.M., C.M., S.B.L., R.N., A.E.J., J.S.T., L.T.), Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Andrea HansenDivision of Hematology/Oncology (K.S.L.M., A.H., A.P., A.E.J., J.S.T.), Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Stephen B LoCancer Outcomes Research and Education Program (K.S.L.M., C.M., S.B.L., R.N., A.E.J., J.S.T., L.T.), Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA; Center for Psychiatric Oncology & Behavioral Sciences (S.B.L.), Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
Veronica DeckerUniversity of Central Florida College of Nursing (V.D.), Lake Nona, Florida, USA.
Christopher R ManzDepartment of Medical Oncology (C.R.M.), Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Aparna ParikhDivision of Hematology/Oncology (K.S.L.M., A.H., A.P., A.E.J., J.S.T.), Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Ryan NippCancer Outcomes Research and Education Program (K.S.L.M., C.M., S.B.L., R.N., A.E.J., J.S.T., L.T.), Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA; Division of Hematology/Oncology (R.N.), Department of Medicine, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA.
Areej El-JawahriDivision of Hematology/Oncology (K.S.L.M., A.H., A.P., A.E.J., J.S.T.), Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Cancer Outcomes Research and Education Program (K.S.L.M., C.M., S.B.L., R.N., A.E.J., J.S.T., L.T.), Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Jennifer S TemelDivision of Hematology/Oncology (K.S.L.M., A.H., A.P., A.E.J., J.S.T.), Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Cancer Outcomes Research and Education Program (K.S.L.M., C.M., S.B.L., R.N., A.E.J., J.S.T., L.T.), Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Lara TraegerCancer Outcomes Research and Education Program (K.S.L.M., C.M., S.B.L., R.N., A.E.J., J.S.T., L.T.), Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA; Department of Psychology (L.T.), University of Miami College of Arts and Sciences, Coral Gables, Florida, USA.

Funding

Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9M
NCI NIH HHS K12 CA087723
6 · The paper itself

Abstract

contextMultimodality therapy for locally advanced rectal cancer (LARC) is lengthy, complex, and overwhelming for patients to navigate. We developed "PATHWAYS," an informational and supportive care intervention tailored to patients initiating multimodality therapy for LARC.

objectivesWe sought to assess the feasibility and acceptability of PATHWAYS, and to refine the intervention based on patient feedback.

methodsWe conducted a pilot randomized controlled trial among patients initiating multimodality therapy for LARC. We randomized participants 1:1 to receive PATHWAYS (an educational guide plus four behavioral coaching sessions) or enhanced usual care (a curated list of online resources). Participants completed questionnaires at baseline, six, and 12 weeks, and in-depth interviews at six and 12 weeks to elicit feedback on study participation. The primary outcome was feasibility (60% of eligible patients enroll; 60% of PATHWAYS participants complete the intervention). The secondary outcome was acceptability (80% of PATHWAYS participants report satisfaction using the Client Satisfaction Questionnaire-8).

resultsAmong 34 eligible patients approached, 20 (59%) enrolled (mean age 56.8 years, 50% women, 75% non-Hispanic White). Of the 10 patients randomized to PATHWAYS, nine (90%) completed the intervention, all (100%) of whom found the intervention acceptable. In qualitative interviews, participants reported using the PATHWAYS guide to enhance knowledge and the coaching sessions to make learning more manageable and tailored to their needs.

conclusionIn this pilot randomized controlled trial, we demonstrated high engagement and acceptability of a novel supportive care intervention for patients with LARC. Study results will guide refinements to the PATHWAYS intervention and future study procedures.

Indexed as

Patient Education as TopicRectal NeoplasmsAdultAgedCombined Modality TherapyFeasibility StudiesFemaleHumansMaleMiddle AgedPatient SatisfactionPilot ProjectsSurveys and QuestionnairesTreatment Outcomelocally advanced rectal cancerMultimodality therapysupportive care intervention

Identifiers

PMID42217757
PMCPMC13288241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.